Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Calidi Biotherapeutics, Inc. Common Stock (NY:CLDI)

0.5448 -0.0362 (-6.23%)
Streaming Delayed Price Updated: 12:41 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Calidi Biotherapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 Next >
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Cancer Platforms, Reports Narrowed Loss for Q4 2024
Via Investor Brand Network
Study Explains Why Melanoma, Other Cancers Evade and Resist Immunotherapy
Via Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs
Via Investor Brand Network
Natural Killer Cells That are Genetically Modified Show Potential in Cancer Immunotherapy
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces $3.9 Million Registered Direct Offering and Private Placement
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Encouraging Progress in Brain Cancer Trial with City of Hope
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments
Via Investor Brand Network
New Study Shows ‘Viral Mimicry’ Could Transform Glioblastoma Treatment
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) Novel Therapies Show Promise Against Aggressive Cancers
Via Investor Brand Network
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Stands at the Forefront of Integrating New Oncology Therapies
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform
Via Investor Brand Network
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) and OS Therapies (NYSE American: OSTX) to Appear on RedChip’s Bloomberg TV Show
Via Investor Brand Network
Exposures Product Safety
Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Launches “CLD-101” Trial for High-Grade Glioma at Northwestern
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focused on Advancing Stem Cell-Based Research Amid Rising Cancer Concerns
Via Investor Brand Network
Which stocks are moving after the closing bell on Wednesday?
The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
These stocks are moving in today's after hours session
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar on Feb. 5
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Ends SEPA Agreement Following Successful Fundraising
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present Breakthrough Virotherapy Platform at AACR 2025
Via Investor Brand Network
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $4.25 Million Public Offering
Via Investor Brand Network
Topics Regulatory Compliance
Exposures Legal Regulatory
Why Calidi Biotherapeutics (CLDI) Stock Is Down 30%
Calidi Biotherapeutics shares are trading lower by 32% during Friday's session. The company priced its public offering of 5 million shares of common stock at $0.85 per share. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Zoomcar Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces Public Offering of Common Stock and Warrants
Via Investor Brand Network
Topics Regulatory Compliance
Exposures Legal Regulatory
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.